title: Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet.
abstract: The effects of indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor content of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma have been examined in female Sprague-Dawley rats. The rats were fed either a high-fat (20% corn oil) or low-fat (0.5% corn oil) diet with or without 0.005% indomethacin starting 7 days after intragastric administration of a single dose of 5 mg 7,12-dimethylbenz(a)anthracene. The results demonstrated that indomethacin completely blocked the stimulatory effect of fat on tumorigenesis, as demonstrated by a decreased tumor incidence, a decreased number of tumors per group, and an increased latency. Contrary to what had been expected, however, indomethacin promoted tumor proliferation in both the high- and low-fat diet groups, as evidenced by an increased tumor size, an increased bromodeoxyuridine-labeling index, and a decreased potential tumor-doubling time. No significant difference in either the estrogen receptor or progesterone receptor content of the tumor was noted. It can be concluded, therefore, that indomethacin significantly reduced tumorigenesis in the high-fat diet group but significantly promoted tumor proliferation in both the high- and low-fat diet groups.
authors.affiliation: Department of Surgery (II), School of Medicine, Kanazawa University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Noguchi
authors.forename: T
authors.initials: T
authors.lastname: Taniya
authors.forename: N
authors.initials: N
authors.lastname: Koyasaki
authors.forename: T
authors.initials: T
authors.lastname: Kumaki
authors.forename: I
authors.initials: I
authors.lastname: Miyazaki
authors.forename: Y
authors.initials: Y
authors.lastname: Mizukami
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors; D004273:DNA, Neoplasm / Q000032:analysis; D004041:Dietary Fats / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D007213:Indomethacin / Q000494:pharmacology*; D007700:Kinetics; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D011919:Rats, Inbred Strains; D011960:Receptors, Estrogen / Q000187:drug effects / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000187:drug effects / Q000378:metabolism*; D013997:Time Factors
chemical_list: D016861:Cyclooxygenase Inhibitors; D004273:DNA, Neoplasm; D004041:Dietary Fats; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D015127:9,10-Dimethyl-1,2-benzanthracene; D007213:Indomethacin